Comparative agents:
Dipeptidyl peptidase-4 inhibitors
Indication:
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Mechanism of action:
Inhibition of the inactivation of incretin hormones that are involved with the regulation of serum glucose levels 
Indication:
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Mechanism of action:
Inhibition of the inactivation of incretin hormones that are involved with the regulation of serum glucose levels; inhibition of hepatic gluconeogenesis 
Comparative agents: None
Indication:
Patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy
Mechanism of action:
Inhibits proliferation and induces apoptosis of tumor cells along with the enhanced T cell-and natural killer cell-mediated immunity and inhibits the production of pro-inflammatory cytokines (eg, TNF-a and IL-6) by monocytes 
